<DOC>
	<DOCNO>NCT02171949</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy multiple infusion mononuclear bone marrow cell patient chronic liver disease .</brief_summary>
	<brief_title>Clinical Trial Evaluation Treatment With Multiple Infusions Mononuclear Bone Marrow Cells Patients With Chronic Liver Diseases</brief_title>
	<detailed_description>This safety/efficacy phase II , open , randomize , control clinical trial , two arm . The study population consist 30 patient chronic decompensated liver disease ( Child-Pugh B C ) . The candidate include study ask voluntarily participate sign write consent . The patient allocate randomly 2 group : group A , patient undergo intervention ; group B , patient control . Patients group receive clinical follow-up . They maintain drug therapy commonly use patient cirrhosis , may include : spironolactone , furosemide , lactulose , metronidazole , neomycin , analogs nucleoside / nucleotide patient hepatitis B , vitamin complex . All patient include Group A undergo cell therapy accord technique describe follow : day 1 ( D-1 ) , patient hospitalize undergo bone marrow puncture iliac crest . 150 200 ml bone marrow aspirate collect . The procedure do local anesthesia sedation . The fraction mononuclear cell isolate aspirated marrow SEPAX ( System cell process ) - Biosafe , Switzerland . The enriched fraction collect mononuclear cell resuspend saline . The obtain cell population analyze flow cytometry characterization , dilute 20 ml saline . The cell inject 3 time throughout study , day 1 ( D-1 ) , 30 ( D-30 ) 60 ( D-60 ) . Patients undergo series clinical laboratory evaluation also submit follow procedure : - Cell blood count - Biochemical analysis ( measurement electrolytes - sodium potassium ) - Renal function test ( urea creatinine ) - Liver profile test ( total protein fraction , bilirubin , prothrombin time , transaminase , alkaline phosphatase , gamma-GT ) - Metabolic profile ( glucose , total cholesterol fraction , triglyceride ) - Thyroid profile test - Serology require blood transfusion bone marrow transplant Brazil - Alpha-fetoprotein - Beta-HCG ( human chorionic gonadotropin ) , woman - Handgrip dynamometer - Treadmill test - Six-minute walk test - Abdomen doppler ultrasound - Magnetic resonance image upper abdomen elastography - Measurement serum factor - Shear wave elastography Also , patient respond question SF ( Short Form ) -36 questionnaire ( assessment quality life ) . Clinical follow-up kept patient suspend participation study adverse event / laboratory abnormality , patient 's desire , follow insurance protocol . In addition clinical surgical follow-up , specific medical care offer patient experience adverse event , stabilization patient , even target date completion study exceed .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Diagnosis liver cirrhosis different etiology , confirm clinical examination , laboratory test , image study / biopsy show process evolution cirrhosis establish cirrhosis ( equivalent Metavir score F3/F4 ) ; Nonparticipation wait list liver transplantation , case participation , allocation fifth position list , subject blood group A O , third position subject blood group ; Absence clinical , laboratory radiological evidence hepatocellular carcinoma ; Absence pregnancy potential negative pregnancy test female patient , impossibility use contraception method study ; Permission puncture iliac crest evaluation preanesthetic visit . Impossibility obtain vascular access percutaneous procedure ; Sepsis ; Hepatic encephalopathy detect screening test ; BuddChiari syndrome ; Severe coagulopathy INR &gt; 2,4 platelet count &lt; 30.000 ; Presence malignancy ( exclude nonmelanoma skin cancer ) ; Decompensated heart failure ; Primary hematologic disease ; Renal failure creatinin &gt; 2,5mg/dl ; Coinfection HIV ; Pregnancy ; Dependence organic medium circulatory ventilatory ; Any comorbidity impact survival 2 year ; Participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Chronic hepatitis</keyword>
	<keyword>Hepatic cirrhosis</keyword>
</DOC>